tixestobart

A monospecific hexamer-forming antibody, based on the HexaBody technology platform, directed against the cell surface antigen CD27, with potential immunostimulatory and antineoplastic activities. Upon administration, tixestobart targets and binds to CD27 expressed on a variety of immune cell types, including most T lymphocytes, and forming a hexamer upon binding. This induces CD27-mediated signaling, and enhances CD27-mediated responses, including the expansion of antigen-activated T cells and natural killer (NK) cells. This restores immune function and leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD27, a co-stimulatory molecule and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T lymphocytes, memory B cells and NK cells. It plays an important role in NK cell-mediated cytolytic activity and T- and B-lymphocyte proliferation and activation.